Clinical Trial to Study Thromboprophylaxis with Apixaban in Pancreatobiliary Malignancies

Strategic Insights -

A clinical trial has been registered to study the efficacy of Apixaban in preventing venous thromboembolism (VTE) in patients with pancreatobiliary malignancies. The trial, registered with the Clinical Research Information Service (CRiS) in the Republic of Korea, aims to determine whether Apixaban can effectively prevent VTE in these high-risk patients. Pancreatobiliary malignancies have a higher risk of VTE, with reported incidence rates ranging from 15-30%. The trial will assess the safety and efficacy of Apixaban in preventing VTE in these patients, and its findings may contribute to the development of more effective thromboprophylaxis strategies.

Key Takeaways:

  • The clinical trial, registered with CRiS, aims to study the efficacy of Apixaban in preventing VTE in patients with pancreatobiliary malignancies.
  • Pancreatobiliary malignancies have a higher risk of VTE, with reported incidence rates ranging from 15-30%.
  • The trial will assess the safety and efficacy of Apixaban in preventing VTE in these patients.
  • NOACs, such as Apixaban, have a lower possibility of gastrointestinal bleeding compared to other NOACs.
  • Apixaban is a convenient oral anticoagulant with fewer interactions with other drugs.
  • The trial is conducting primary prevention of VTE in patients with pancreatobiliary malignancies.

Statistics:

  • 15-20% of cancer patients develop VTE.
  • 20-30% of pancreatic cancer patients develop thromboembolism.
  • 20% of patients with biliary tract tumors develop thromboembolism.
  • The risk of thromboembolism increases fivefold in patients undergoing chemotherapy.

Sources:

  • **Clinical Research Information Service (CRIS) - Republic of Korea**

https://cris.nih.go.kr/cris/search/detailSearch.do?seq=29868&search_page=L